Appendix 4D
Released
Released
Announcement PDF
IMAGION BIOSYSTEMS LIMITED
APPENDIX 4D
FOR THE HALF-YEAR ENDED 30 JUNE 2022
1
1. Reporting period (“current period”):
Previous corresponding periods:
Half-year ended 30 June 2022
Half-year ended 30 June 2021
Year ended 31 December 2021
2. Results for announcement to the market
Item
Revenue
(Loss) from ordinary activities after tax
attributable to members
Net (loss) for the period attributable to
members
Movement
$AUD
Down
Up
90.4%
297.2%
to
to
265,763
(5,760,270)
Up
319.5%
to
(5,374,809)
Dividends
There were no dividends paid, recommended or declared during the current period.
3. Consolidated Statement of Profit and Loss and Other Comprehensive Income
Refer to the attached Financial Statements together with notes for the half-year ended 30 June 2022.
4. Consolidated Statement of Financial Position
Refer to the attached Financial Statements together with notes for the half-year ended 30 June 2022.
5. Consolidated Statement of Cash Flows
Refer to the attached Financial Statements together with notes for the half-year ended 30 June 2022.
6. Consolidated Statement of Changes in Equity
Refer to the attached Financial Statements together with notes for the half-year ended 30 June 2022.
7. Dividends
Current period:
There were no dividends paid, recommended or declared during the period.
Previous period:
There were no dividends paid, recommended or declared during the previous financial period.
8. Dividend reinvestment plans
There are no dividend reinvestment plans operation.
9. Net tangible assets
30 Jun 2022
$AUD
31 Dec 2021
$AUD
0.0074
0.0119
Net tangible asset backing per ordinary
share
10. Details of entities over which control has been gained or lost
N/A
11. Details of associates and joint venture entities
N/A
2
12. Any other significant information
N/A
13. Foreign Entities
Details of origin of Accounting Standards of foreign subsidiary:
Imagion Biosystems Limited owns 100% of Imagion Biosystems Inc. This company prepares their financial
statements in accordance with International Financial Reporting Standards (IFRS) as issued by the
International Accounting Standards Board (IASB).
14. Results for the period
Refer to the Review of Operations contained within the attached Imagion Biosystems Limited Half-Year
Financial Report for the half-year ended 30 June 2022.
15. Status of Review
The Half-Year Financial Report has been independently reviewed.
16. Description of any likely review dispute or qualification:
The Half-Year Financial Report is not subject to a qualified independent review statement.
3
Share your feedback
Discover